CIRCULATING OXIDIZED LOW-DENSITY LIPOPROTEIN LEVELS IN AN EARLY STAGE OF ACUTE ISCHEMIC STROKE
Keywords:
oxLDL, stroke, cardivascular diseaseAbstract
Introduction: Atherosclerosis remains the most common cause of coronary artery disease (CAD) and cerebral or peripheral artery disease. At present, lipid peroxidation is considered one of the basic mechanisms involved in the initiation and progression of many diseases. An oxidative stress resulting in lipid peroxidation and protein modification is involved in the pathogenesis of atherosclerosis and cardiovascular diseases.
Aim: The primary aim of this study was to determine the circulating levels of oxidized low-density lipoprotein (ox-LDL) in patients with acute stages of ischemic stroke. The secondary aim was to evaluate if there was an association between ox-LDL concentration and conventional lipid risk factors for cardiovascular diseases (CVD).
Material and methods: Seventy-five patients with acute ischemic stroke (AIS) and ninety control subjects without cardiovascular risk factors were included in the study. Total cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol were measured in patients as well as in control subjects by enzymatic methods on Roche C311 Cobas Analyzer. Ox-LDL was measured by the sandwich ELISA technique.
Results: There was no significant difference in BMI, total cholesterol, triglycerides, HDL-c, and LDL-c between the two groups. There was a significant difference between patients with AIS and the control group regarding ox-LDL concentrations (p=0.03). We did not find any significant correlation between plasma ox-LDL concentration and lipid parameters.
Conclusions: Levels of circulating ox-LDL were elevated in patients with acute ischemic stroke. Ox-LDL levels were not statistically correlated with major lipid risk factors for CVD. Therefore, ox-LDL levels may represent a novel risk marker of CVD.
References
Heron M. Deaths: Leading Causes for 2017. Natl Vital Stat Rep 2019; 68(6): 1-77. PMID: 32501203.
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 2019; 139(10): e56-e528. doi: 10.1161/CIR.0000000000000659.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2095-2128. doi: 10.1016/S0140-6736(12)61728-0.
Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, et al. Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014; 383(9913): 245-54. doi: 10.1016/s0140-6736(13)61953-4.
Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983; 52: 223-261. doi: 10.1146/annurev.bi.52.070183.001255.
Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30(12): 2311-2316. doi: 10.1161/ATVBAHA.108.179697.
van Dijk RA, Kolodgie F, Ravandi A, Leibundgut G, Hu PP, Prasad A et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012; 53(12): 2773-2790. doi: 10.1194/jlr.P030890.
Obermayer G, Afonyushkin T, Binder CJ. Oxidized low-density lipoprotein in inflammation-driven thrombosis. J Thromb Haemost 2018; 16(3): 418-428. doi: 10.1111/jth.13925.
Chen C, Khismatullin DB. Oxidized low-density lipoprotein contributes to atherogenesis via co-activation of macrophages and mast cells. PLoS One 2015; 10(3): e0123088. doi: 10.1371/journal.pone.0123088.
Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol 2012; 60(21): 2218-2229. doi: 10.1016/j.jacc.2012.08.979.
Chen KC, Liao YC, Wang JY, Lin YC, Chen CH, Juo SH. Oxidized low-density lipoprotein is a common risk factor for cardiovascular diseases and gastroenterological cancers via epigenomical regulation of microRNA-210. Oncotarget 2015; 6(27): 24105-24118. doi: 10.18632/oncotarget.4152.
Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013; 2013: 152786. doi: 10.1155/2013/152786.
Mäkelä KM, Traylor M, Oksala N, Kleber ME, Seppälä I, Lyytikäinen LP, Hernesniemi JA, et al. Wellcome Trust Case Control Consortium 2 (WTCCC2); Delgado G, Grammer TB, Scharnagl H, Markus HS, März W, Lehtimäki T. Association of the novel single-nucleotide polymorphism which increases oxidized low-density lipoprotein levels with cerebrovascular disease events. Atherosclerosis 2014; 234(1): 214-217. doi: 10.1016/ j.atherosclerosis.2014.03.00.
Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103(15): 1955-1560. doi.org/10.1161/01.CIR.103.15.1955.
Guldiken B, Guldiken S, Turgut B, Turgut N, Demir M, Celik Y, et al. The roles of oxidized low-density lipoprotein and interleukin-6 levels in acute atherothrombotic and lacunar ischemic stroke. Angiology 2008; 59(2): 224-229. doi: 10.1177/0003319707304134.
Tsai NW, Chang YT, Huang CR, Lin YJ, Lin WC, Cheng BC, et al. Association between oxidative stress and outcome in different subtypes of acute ischemic stroke. Biomed Res Int 2014; 2014: 256879. doi: 10.1155/2014/25687917.
Tsai NW, Hung SH, Huang CR, Chang HW, Chang WN, Lee LH, et al. The association between circulating endothelial progenitor cells and outcome in different subtypes of acute ischemic stroke. Clin Chim Acta 2014; 427: 6-10. doi: 10.1016/j.cca.2013.09.029.
Tsai NW, Lee LH, Huang CR, Chang WN, Chang YT, Su YJ, et al. Statin therapy reduces oxidized low density lipoprotein level, a risk factor for stroke outcome. Crit Care 2014; 18(1): R16. doi: 10.1186/cc13695.
Bui MN, Sack MN, Moutsatsos G, Lu DY, Katz P, McCown R, et al. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J 1996; 131(4): 663-667. doi: 10.1016/s0002-8703(96)90268-9.
Puurunen M, Mänttäri M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154(22): 2605-2609. PMID: 7979858.
Ziouzenkova O, Asatryan L, Akmal M, Tetta C, Wratten ML, Loseto-Wich G, Jürgens G, Heinecke J, Sevanian A. Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J Biol Chem 1999; 274(27): 18916-18924. doi: 10.1074/jbc.274.27.18916.
